Login to Your Account



NewCo News: Spring Bank Targets Hepatitis B Market with Small-Molecule Tech

By Marie Powers


Friday, June 3, 2011
A small biotech that has flown under the radar for nearly a decade may be poised to make an impact in the global hepatitis B space. Spring Bank Pharmaceuticals Inc. expects to file an investigational new drug (IND) application with the FDA this year for SB 9200, an orally bioavailable hepatitis B drug based on the company's small molecule nucleic acid hybrid (SMNH) technology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription